Stock analysts at Royal Bank Of Canada initiated coverage on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a research note issued on Thursday, The Fly reports. The firm set a “sector perform” rating on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the company. Canaccord Genuity set a $484.00 target price on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, June 20th. BTIG Research reissued a “buy” rating and set a $540.00 target price (up from $480.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, June 30th. BidaskClub cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 6th. Bank of America Corporation reissued a “buy” rating and set a $593.00 target price (up from $589.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. Finally, Citigroup Inc. boosted their target price on Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the company a “buy” rating in a research note on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $496.35.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.81% during trading on Thursday, hitting $441.30. The company had a trading volume of 873,444 shares. Regeneron Pharmaceuticals has a 1-year low of $325.35 and a 1-year high of $543.55. The company’s 50 day moving average is $479.23 and its 200 day moving average is $445.02. The firm has a market capitalization of $46.79 billion, a P/E ratio of 44.27 and a beta of 1.65.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. During the same period in the previous year, the firm earned $2.82 earnings per share. The business’s revenue was up 21.2% compared to the same quarter last year. Analysts anticipate that Regeneron Pharmaceuticals will post $14.90 earnings per share for the current fiscal year.

WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Now Covered by Analysts at Royal Bank Of Canada” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/14/regeneron-pharmaceuticals-inc-regn-now-covered-by-analysts-at-royal-bank-of-canada.html.

In other Regeneron Pharmaceuticals news, SVP Michael S. Aberman sold 2,269 shares of the stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $532.42, for a total value of $1,208,060.98. Following the transaction, the senior vice president now owns 9,193 shares of the company’s stock, valued at $4,894,537.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Neil Stahl sold 8,306 shares of the stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total value of $4,423,360.30. Following the completion of the transaction, the executive vice president now directly owns 43,950 shares in the company, valued at approximately $23,405,572.50. The disclosure for this sale can be found here. In the last three months, insiders sold 120,690 shares of company stock worth $57,732,183. 10.40% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of REGN. Gabelli Funds LLC increased its position in Regeneron Pharmaceuticals by 13.3% in the first quarter. Gabelli Funds LLC now owns 6,800 shares of the biopharmaceutical company’s stock worth $2,635,000 after buying an additional 800 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in Regeneron Pharmaceuticals by 30.2% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 5,641 shares of the biopharmaceutical company’s stock worth $2,186,000 after buying an additional 1,307 shares in the last quarter. TFS Capital LLC purchased a new stake in Regeneron Pharmaceuticals in the first quarter worth about $480,000. Toronto Dominion Bank increased its position in Regeneron Pharmaceuticals by 57.4% in the first quarter. Toronto Dominion Bank now owns 20,540 shares of the biopharmaceutical company’s stock worth $7,958,000 after buying an additional 7,487 shares in the last quarter. Finally, NEXT Financial Group Inc increased its position in Regeneron Pharmaceuticals by 2.3% in the first quarter. NEXT Financial Group Inc now owns 916 shares of the biopharmaceutical company’s stock worth $356,000 after buying an additional 21 shares in the last quarter. 67.96% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

The Fly

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.